Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS‐13 activity levels in inhibitor‐treated rats by the use of defined doses of recombinant ADAMTS‐13
Plaimauer, B., Schiviz, A., Kaufmann, S., Höllriegl, W., Rottensteiner, H., Scheiflinger, F.
Published in Journal of thrombosis and haemostasis (01.11.2015)
Published in Journal of thrombosis and haemostasis (01.11.2015)
Get full text
Journal Article
Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura
Kopić, A., Benamara, K., Piskernik, C., Plaimauer, B., Horling, F., Höbarth, G., Ruthsatz, T., Dietrich, B., Muchitsch, E.‐M., Scheiflinger, F., Turecek, M., Höllriegl, W.
Published in Journal of thrombosis and haemostasis (01.07.2016)
Published in Journal of thrombosis and haemostasis (01.07.2016)
Get full text
Journal Article
Influence of genetic background on bleeding phenotype in the tail‐tip bleeding model and recommendations for standardization: communication from the SSC of the ISTH
Schiviz, A., Magirr, D., Leidenmühler, P., Schuster, M., Muchitsch, E.‐M., Höllriegl, W.
Published in Journal of thrombosis and haemostasis (01.11.2014)
Published in Journal of thrombosis and haemostasis (01.11.2014)
Get full text
Journal Article
BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation
Turecek, P L, Bossard, M J, Graninger, M, Gritsch, H, Höllriegl, W, Kaliwoda, M, Matthiessen, P, Mitterer, A, Muchitsch, E-M, Purtscher, M, Rottensteiner, H, Schiviz, A, Schrenk, G, Siekmann, J, Varadi, K, Riley, T, Ehrlich, H J, Schwarz, H P, Scheiflinger, F
Published in Hämostaseologie (2012)
Published in Hämostaseologie (2012)
Get more information
Journal Article